|
Vaccine Detail
Cancer DNA vaccine p.DOM-AH1 encoding fragment C |
Vaccine Information |
- Vaccine Name: Cancer DNA vaccine p.DOM-AH1 encoding fragment C
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0004425
- Type: DNA vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Mouse
- Fragment C from tetanus toxin
gene engineering:
- Type: DNA vaccine construction
- Description: This DNA vaccine expressed the first domain of fragment C (FrC)3 from tetanus toxin (DOM; TT865–1120) with sequence encoding the AH1 CTL epitope fused to the 3 terminus (Buchan et al., 2005).
- Detailed Gene Information: Click Here.
- DNA vaccine plasmid:
- DNA vaccine plasmid name:
- DNA vaccine plasmid VO ID: VO_0000132
- Immunization Route: Intramuscular injection (i.m.)
|
Host Response |
Mouse Response
- Vaccine Immune Response Type: VO_0000286
- Immune Response: Vaccination was rendered effective by electroporation, priming higher levels of AH1-specific CD8(+) T cells able to protect mice from tumor growth (Buchan et al., 2005).
- Efficacy: Delivery in a suboptimal volume (2 × 10 μl) did not mediate protection. However, protective efficacy was completely restored when suboptimal volume was combined with electroporation (p < 0.003). Therefore, this vaccine was able to protect from CT26 tumor in vivo (Buchan et al., 2005).
|
References |
Buchan et al., 2005: Buchan S, Grønevik E, Mathiesen I, King CA, Stevenson FK, Rice J. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen. Journal of immunology (Baltimore, Md. : 1950). 2005; 174(10); 6292-6298. [PubMed: 15879128].
|
|